Back to Search Start Over

Enzymatic detection of α-hydroxybutyrate, an important marker of insulin resistance, and comparison with LC-MS/MS detection.

Authors :
Steiner B
Leitner C
Stadler D
Prugger EM
Magnes C
Herzog PL
Source :
Practical laboratory medicine [Pract Lab Med] 2024 May 06; Vol. 40, pp. e00398. Date of Electronic Publication: 2024 May 06 (Print Publication: 2024).
Publication Year :
2024

Abstract

Aim: The metabolite α-hydroxybutyrate (α-HB) is an important marker of insulin resistance and impaired glucose tolerance allowing to identify patients at risk of developing diabetes and related metabolic disorders before any symptoms become apparent. At present, its exact quantification requires mass spectrometry (LC-MS), which is not compatible with routine laboratory use. Accordingly, a simple enzymatic-based method was assessed and its applicability and measuring accuracy compared with LC-MS was investigated.<br />Methods: Standards, serum, and plasma samples containing α-HB were prepared with routine procedures and their α-HB contents measured with the XpressGT® enzymatic test kit photometrically or with LC-MS and multiple reaction monitoring.<br />Results: α-HB detection with XpressGT® yielded highly linear calibration curves and 102 % recovery of stocks added to commercial samples. Stability of the analyte in serum and plasma samples prepared with various anti-coagulants was >90 % after 46 h for several widely used preparations and recovery after 3 freeze-thaw cycles was ≥95 % with these anti-coagulants. A direct comparison of 75 samples indicated very good agreement of α-HB levels determined by both methods, 86 % of XpressGT® samples being within ±20 % of LC-MS values and even 93 % within ±20 % considering only samples above 30 μM concentration.<br />Conclusion: XpressGT®-based detection of α-HB is an easily applicable method which can be used for accurate and reliable quantification of the metabolite in clinical practice. Routine α-HB determination in patients at risk of developing diabetes would allow early establishment of preventive measures or pharmacological intervention reducing the risk for the onset of serious diabetes-related health problems.<br />Competing Interests: The authors Beate Steiner, Christian Leitner, David Stadler and Peter L. Herzog are employees of DirectSens GmbH. The remaining authors Eva-Maria Prugger and Christoph Magnes declare that there is no conflict of interests regarding the publication of this article.<br /> (© 2024 DirectSens GmbH.)

Details

Language :
English
ISSN :
2352-5517
Volume :
40
Database :
MEDLINE
Journal :
Practical laboratory medicine
Publication Type :
Academic Journal
Accession number :
38745675
Full Text :
https://doi.org/10.1016/j.plabm.2024.e00398